Paul Musco, MD
Ophthalmology · Cranston, RINPI 1063579886
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $117 of the $148 with a category attached, or 79.0%. Regeneron Healthcare Solutions, Inc. accounts for 60.5% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $59, 4.3 times the $14 reported in 2019. That places this record below the midpoint for ophthalmology clinicians in RI, where the typical reported total is $781.
Across 6 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$90
- Alcon$31
- Genentech USA, Inc.$14
- Johnson & Johnson Vision Care, Inc.$14
What the payments were for
- Food & beverage$11779%
- Education$3121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $90 |
| Alcon | 1 | $31 |
| Genentech USA, Inc. | 1 | $14 |
| Johnson & Johnson Vision Care, Inc. | 1 | $14 |
How this compares
$148 in reported general payments places this provider in the 25th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 27 | $18,325 |
| RestasisCyclosporine | 19 | $11,422 |
| LumiganBimatoprost | 14 | $8,507 |
| Travoprost | 13 | $4,895 |
| Latanoprost | 371 | $4,425 |
| Timolol Maleate | 171 | $4,181 |
| Brimonidine Tartrate | 44 | $3,182 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 141 | $1,317 |
| Prednisolone Acetate | 27 | $1,286 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $1,207 |
| ErythromycinErythromycin Base | 103 | $1,073 |
| Minocycline Hcl | 11 | $585 |
| Dorzolamide Hcl | 34 | $578 |
| Doxycycline Hyclate | 23 | $252 |
| Diclofenac Sodium | 24 | $215 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Cranston
- Alexander CalendaCranston$781
- Sarah AnisProvidence$163K
- Sarah LevyWakefield$148K
- Nermin GraiseWarwick$60K
- Jesse RichmanProvidence$30K
- Alex GerberMiddletown$15K
- Yoash EnzerProvidence$11K
- Giulio DiamanteJohnston$6K
- David TienProvidence$6K
- Leah KammerdienerWarwick$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.